In its announcement of the acquisition, Regeron claimed it would ensure that customers’ personal data including genetic and ...

Schrödinger is laying off 60 staffers, or about 7% of its workforce, in an effort to save cash and boost efficiency. | ...

"While the rescinded grant is undoubtedly a setback, it also sharpens our focus on the solid foundation already established ...

Alacrita, a leading life science consulting firm, has expanded its biotech investment and fundraising advisory services with the appointment of Lucas Rodriguez, PhD, as Partner. Dr. Rodriguez will ...

Pfizer on Tuesday announced a cancer drug licensing deal with Chinese biotech 3SBio that includes a $1.25 billion upfront ...

Viking Therapeutics offers leaner operations, lower complexity, faster trial execution, and less execution risk. Learn more ...

Biotech firm Synthego files for bankruptcy despite a purchase agreement with Perceptive Advisors and plans for operational ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Debates over AI antibody design terminology have clouded the industry’s shared mission of bringing better therapeutics to the ...

Pfizer PFE announced that it is in-licensing global development and commercialization rights, ex-China, to SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, from Chinese biotech, 3SBio. 3SBio ...

In the Phase 2 study of patients with chronic kidney disease, the highest dose of the drug lowered by 86% the levels of ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio. Cylembio ® is a ...